Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
WT1
Name:
WT1 transcription factor
Location:
11p13
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT00153608 | WT1 Peptid Vaccination in Carcinomas | View | |
| NCT01220128 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | View | |
| NCT00433745 | Wilms Tumor 1 WT1 Peptide Vaccine for High Risk Hematologic Malignancy | View | |
| NCT00488592 | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | View | |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | View | |
| NCT00923910 | Wilms Tumor 1 Protein Vaccine to Treat Cancers of the Blood | View | |
| NCT01266083 | WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia AML or Acute Lymphoblastic Leukemia ALL | View | |
| NCT01706185 | Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer | View | |
| NCT02475707 | Administration of Donor MultiTAA-Specific T Cells for ALL | View | |
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS ADSPAM | View | |
| NCT02686424 | Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy ONCO-RD 010 CRT | View | |
| NCT00270452 | Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome | View | |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | View | |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma | View | |
| NCT01051063 | Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy | View | |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | View | |
| NCT06456359 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor | View | |
| NCT01621542 | Clinical Study of WT2725 in Patients With Advanced Malignancies | View | |
| NCT01291420 | Dendritic Cell Vaccination for Patients With Solid Tumors | View | |
| NCT01334060 | WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation | View | |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | View | |
| NCT02550535 | A Phase III Study of Gene-modified WT1 TCR Therapy in MDS AML Patients | View | |
| NCT01252901 | Registry for Patients With Wilms Tumor Suppressor Gene 1 WT1 Mutation Associated Diseases | View | |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia A Phase III Safety and Toxicity Study | View | |
| NCT00834002 | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission | View | |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients | View | |
| NCT01265433 | Galinpepimut-S WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | View | |
| NCT01314391 | Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor | View | |
| NCT01475370 | Study of OCV-501 in Patients With Acute Myeloid Leukemia AML Extension From Study 311-10-001 | View | |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia Myelodysplastic Syndrome or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | View | |
| NCT01686334 | Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission | View | |
| NCT01758328 | Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With RelapsedRefractory Multiple Myeloma | View | |
| NCT01819558 | Phase III Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy | View | |
| NCT01837511 | Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I II and III Non-Small Cell Lung CancerNSCLC in Asiatic Patients | View | |
| NCT01995708 | CT7 MAGE-A3 and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | View | |
| NCT04040231 | Using a Targeted Cancer Vaccine Galinpepimut-S With Immunotherapy Nivolumab in Mesothelioma | View | |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma | View | |
| NCT02714790 | Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia | View | |
| NCT05755633 | Role of Day 60 WT1 Assessment on Bone Marrow in Predicting Relapse and Mortality After Allogeneic Stem Cell Transplantation | View | |
| NCT05765084 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1DC Vaccination Into PlatinumPemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | View | |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | View | |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | View | |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCsCellgramDC-WT1 and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy | View | |
| NCT01842139 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | View | |
| NCT04747002 | Investigator-initiated Clinical Trial Phase II of Cancer Vaccine Dainippon Sumitomo PhamaDSP-7888 for Acute Myeloid Leukemia Patients | View | |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | View | |
| NCT00562640 | Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer Primary Peritoneal Cavity Cancer or Fallopian Tube Cancer Fludarabine Treatment Closed as of 12012009 | View | |
| NCT04837196 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | View | |
| NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | View | |
| NCT05360680 | A Phase 1 in Patients With HLA-A0201 and WT1 RecurrentMetastatic Cancers | View | |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome Acute or Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | View | |
| NCT02895412 | Infection and Tumour Antigen Cellular Therapy | View | |
| NCT00909168 | Induction Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia AML | View | |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors | View | |
| NCT01385787 | MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia | View | |
| NCT01440920 | A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients | View | |
| NCT00725283 | Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia AML | View | |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia | View | |
| NCT00179829 | WT1 for the Detection of Minimal Residual Disease | View | |
| NCT00153582 | WT1 Peptide Vaccination in Acute Myeloid Leukemia AML | View | |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation | View | |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | View | |
| NCT02737787 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | View | |
| NCT02770820 | Laboratory-Treated Central MemoryNaive CD8 T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | View | |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | View | |
| NCT03311815 | Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing NGS in Patients Diagnosed With Acute Myeloid Leukemia | View | |
| NCT03652545 | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease | View |